Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.

@article{Hinojosa2007EfficacyAS,
  title={Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial.},
  author={J. Cantero Hinojosa and Fernando Gomoll{\'o}n and Santiago Vega Garc{\'i}a and Guillermo Bastida and Jos{\'e} L Cabriada and Cristina Saro and Daniel Ceballos and M{\'o}nica Pe{\~n}ate and Miquel Angel Gassull},
  journal={Alimentary pharmacology & therapeutics},
  year={2007},
  volume={25 4},
  pages={409-18}
}
BACKGROUND The use of tumour necrosis factor antagonists has changed the therapeutic approach to Crohn's disease. AIM To determine response and remission rates associated with the 4-week induction phase of adalimumab treatment in patients with luminal and/or fistulizing Crohn's disease, who have lost response to or become intolerant of infliximab. METHODS In this multicentre, prospective, open-label, observational, 52-week study, 50 adults received an induction dose of adalimumab (160 mg at… CONTINUE READING
30 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 30 extracted citations

Similar Papers

Loading similar papers…